Table 3. Results of association analysis between HLA types and CM-SJS/TEN with SOC in Group 2 (NIHS).
| Carrier frequency (%) | Dominant model analysis | ||||
|---|---|---|---|---|---|
| HLA genotype | Case (n = 20) | Control (n = 220) | P | Pc | Odds ratio (95% CI) |
| HLA-A | |||||
| A*02:06 | 9/20 (45.0%) | 30/220 (13.6%) | 0.0014 | 0.00560 | 5.18 (1.98–13.56) |
| A*03:01 | 0/20 (0%) | 19/220 (8.6%) | 0.3804 | ||
| A*11:01 | 2/20 (10.0%) | 39/220 (17.7%) | 0.5408 | ||
| A*24:02 | 14/20 (70.0%) | 132/220 (60.0%) | 0.4770 | ||
| HLA-B | |||||
| B*13:01 | 2/20 (10%) | 6/220 (2.7%) | 0.1364 | ||
| B*15:01 | 2/20 (10%) | 39/220 (17.7%) | 0.5408 | ||
| B*44:02 | 0/20 (0%) | 4/220 (1.8%) | 1.0000 | ||
| B*44:03 | 8/20 (40.0%) | 30/220 (13.6%) | 0.0058 | 0.0406 | 4.22 (1.59–11.19) |
| B*46:01 | 2/20 (10%) | 18/220 (8.2%) | 0.6764 | ||
| B*52:01 | 1/20 (5.0%) | 48/220 (21.8%) | 0.0857 | ||
| B*54:01 | 5/20 (25%) | 33/220 (15.0%) | 0.3316 | ||
| HLA-C | |||||
| C*03:04 | 6/20 (30%) | 43/220 (19.5%) | 0.2573 | ||
| C*05:01 | 0/20 (0%) | 4/220 (1.8%) | 1.0000 | ||
| C*12:02 | 1/20 (5.0%) | 47/220 (21.4%) | 0.1388 | ||
P: p-values obtained by Fisher's exact tests are shown.
Pc: p-values corrected for the mutiplicity of testing by the number of comparisons: (4, 7 and 3 for HLA-A, HLA-B and HLA-C, respectively).
CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.
SOC: severe ocular surface complications.
CI: Confidence interval.